A Study of LY3303560 in Healthy Participants and Participants With Alzheimer's Disease (AD)

Phase 1

Completed

• Conditions: Alzheimer's Disease
• Interventions: Drug: Saline Solution - IV; Drug: LY3303560 - IV; Drug: LY3303560 - SC

• Registration Number: NCT02754830
• Lead Sponsor: Eli Lilly and Company

Brief Summary

The purpose of this study is to evaluate the safety and tolerability of the study drug, LY3303560. Side effects and laboratory results will be monitored. This study will involve single doses of LY3303560 administered intravenously (IV), meaning into a vein or subcutaneously (SC), meaning under the skin.

Screening is required within 28 days before the start of the study for healthy participants and within 70 days before the start of the study for AD participants. The study requires about 16 weeks of each participant's time including a 4 day clinical research unit (CRU) admission and 10 follow-up appointments.

This is the first time that this study drug is being given to participants. This study is for research purposes only, and is not intended to treat any medical condition.

Detailed Description

Not available

Study Timeline

• Study Start: 2016-04-25
• Study First Submitted: 2016-04-26
• Study First Submitted QC: 2016-04-26
• Study First Posted: 2016-04-28
• Primary Completion: 2018-07-10
• Study Completion: 2018-07-10
• Results First Submitted: 2022-11-11
• Results First Submitted QC: 2022-11-11
• Results First Posted: 2023-09-21
• Status Verified: 2023-10
• Last Update Submitted: 2023-10-06
• Last Update Posted: 2023-10-13

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 72

Inclusion Criteria

• Overtly healthy males or females of non-childbearing potential and who have given consent and are reliable and willing to make themselves available for the duration of the study and are willing to follow study procedures
• AD participants must be at least 50 years of age and have diagnostic criteria consistent with either mild cognitive impairment due to AD or mild-to moderate AD and have a positive florbetapir positron emission tomography (PET) scan

Read More

Exclusion Criteria

• Have known allergies to LY3303560, related compounds or any components of the formulation, or history of significant atopy
• Have an increased risk of seizures
• For AD participants, evidence of macrohemorrhage or greater than 4 microhemorrhage by magnetic resonance imaging (MRI)

Read More

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Saline Solution	Saline Solution - IV	Single IV infusion of saline solution to match LY3303560 on Day 1 in healthy participants.
LY3303560	LY3303560 - IV	Single IV infusion 7 milligram (mg), 21 mg, 70 mg, 210 mg, 700 mg, 1400 mg, 2800 mg, and 5600 mg of LY3303560 on Day 1 in healthy participants.
LY3303560 Subcutaneous (SC)	LY3303560 - SC	Single SC injection of 210 mg LY3303560 on Day 1 in healthy participants.

Primary Outcome Measures

Name	Time	Method
Number of Participants With One or More Serious Adverse Event(s) (SAEs) to be Related to Study Drug Administration	Baseline up to 146 days	Number of participants with one or more SAEs considered by the investigator to be related to study drug administration. A summary of other nonserious adverse events (AEs), and all SAE's, regardless of causality, is located in the Reported Adverse Events section.

Secondary Outcome Measures

Name	Time	Method
Mean Change From Baseline in QT/QT Corrected (QTc) Interval	Baseline, 7 days postdose	Mean change from baseline in QT/QTc intervals using Fridericia's formula \[Fridericia's corrected QT(QTcF)\] from ECG monitoring.
Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve From Time 0 to Infinity (AUC[0-∞]) of LY3303560	Day 1: Predose, 0.5, 2, 4, 12, 24, 48, 72, 96, 120, 144, 360, 528, 696, 1032, 1368, 1704, 2040 hours post-dose; additionally, for 2800 mg and 5600 mg: 2712 and 3384 hours postdose	Serum PK: AUC. Statistical analysis was not pre-specified.
PK: Maximum Drug Concentration (Cmax) of LY3303560	Day 1: Predose, 0.5, 2, 4, 12, 24, 48, 72, 96, 120, 144, 360, 528, 696, 1032, 1368, 1704, 2040 hours post-dose; additionally, for 2800 mg and 5600 mg: 2712 and 3384 hours postdose	Serum PK: Cmax. Statistical analysis was not pre-specified.
Pharmacokinetics (Cerebrospinal Fluid): Maximum Drug Concentration (Cmax) of LY3303560 in Participants With Alzheimer's' Disease (AD)	Day 1: Predose, 0, 2, 4, 12, 24, and 36 hours post-dose
Pharmacokinetics (Cerebrospinal Fluid): Area Under the Concentration Versus Time Curve (AUC) of LY3303560 in Participants With Alzheimer's' Disease (AD)	Day 1: Predose, 0, 2, 4, 12, 24, and 36 hours post-dose

Trial Locations

Locations (2)

PAREXEL-Phase 1 Baltimore Harbor Hospital Center; 🇺🇸 Baltimore, Maryland, United States

Parexel Early Phase Unit at Glendale; 🇺🇸 Glendale, California, United States